ArticleCase reports in oncology
Chronic Enterovirus Meningitis with Acute Hepatitis in a Patient with Chronic Lymphocytic Leukemia Treated with Venetoclax/Obinutuzumab: A Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases.Multiple sclerosis journal - experimental, translational and clinicalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: Enterovirus infection is typically asymptomatic with rapid host clearance. However, several cases of disseminated enterovirus infection in oncologic patients with obinutuzumab-induced hypogammaglobulinemia have been reported in the literature, the majority of whom developed symptoms while actively receiving obinutuzumab. Case Presentation: We present a patient with hypogammaglobulinemia, likely induced by obinutuzumab for chronic lymphocytic leukemia, found to have enterovirus meningitis and hepatitis, with elevated transaminases, headache, and relapsing fevers as primary manifestations of disease. This is the first reported case of a patient developing disseminated enterovirus infection 1 year after discontinuation of obinutuzumab course. After diagnosis, the patient was started on intravenous immune globulin therapy with improvement in symptoms and laboratory abnormalities. Conclusion: Physicians should maintain a high index of suspicion for enterovirus infection in venetoclax/obinutuzumab-treated oncologic patients presenting with nonspecific symptoms including cyclic fevers, headache, myalgias, and elevated liver function tests. Lumbar puncture should be conducted early in the presentation in patients reporting headache or other central nervous system symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.